Diabetes millitus is considered one of the largest emerging threats to health in the 21st century. It has been associated with an impaired innate immune response such as lower respiratory burst function and, consequently, an increase in susceptibility to infection.

Type 2 Diabetes (T2D) patients are known to suffer from comprimised respiratory burst function. It makes them vulnerable to infection-related complications such as chronic wounds that represent a major public health problem in diabetics commonly leading to limb amputation.

FPP® corrects deficit in neutrophil respiratory burst capacity of T2D patients and consequently strengthens the ability of the body to fight infections. It also increases angiogenesis locally, thus promoting the healing process.

FPP® may influence multiple aspects of wound healing: wound infection management, local perfusion (wound cleansing via inflammatory response) up to angiogenesis.

Although it is composed mainly of carbohydrates, FPP® has no impact on patients’ fasting blood glucose, glucose levels, or lipid profile. It can therefore be safely used by people with diabetes.